KANSAS CITY, Kan., July 30, 2015 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX ), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today announced that its strategic partner VetStem Biopharma, Inc. has shared positive results from a dose confirmation study of AT-016, an adipose-derived allogeneic stem cell product exclusively licensed to Aratana for the treatment of osteoarthritis pain in dogs. The double-blinded, multi-site, placebo-controlled field efficacy trial enrolled approximately 90 dogs with osteoarthritis. The dogs who received a single intra-articular injection of AT-016 demonstrated a statistically significant improvement in treatment versus placebo (p&LT0.05). The primary endpoint was treatment success based on the Client Specific Outcome Measurement (CSOM) on day 60.